
Sign up to save your podcasts
Or


Digital therapeutics are growing in popularity for patients. Combining science and technology creates a double-edge sword including one how to best establish quality and trust in the safety and efficacy of patients.
Maria Palombini, Director of Emerging Communities & Opportunities Development and Healthcare Life Sciences (HLS) Practice Lead at IEEE Standards Association (IEEE SA), Michael Ambrose, Director of Product Quality and Analytical Process at USP about establishing standards in digital therapeutics to assure quality and build trust with patients -- the core of the healthcare ecosystem.
Related Resources:
In an effort to enhance clinical research, Maria Palombini, Director of Emerging Communities & Opportunities Development and Healthcare & Life Sciences (HLS) Practice Lead at the IEEE Standards Association (IEEE SA), interviews Jennifer Goldsack, Executive Director of Digital Medicine Society (DiME) to explore the need for bringing together pharmaceutical clinical researchers and technologists to compel device makers to embrace and develop open source and compatible technologies.
Related Sources:
Maria Palombini, Director of Emerging Communities & Opportunities Development and Healthcare & Life Sciences (HLS) Practice Lead at the IEEE Standards Association (IEEE SA), interviews Walter De Brouwer, CEO & Founder of Doc.ai and Chair of the IEEE SA Technology and Data Harmonization for Enabling Decentralized Clinical Trials Industry Connections (IC) Program to discuss decentralizing clinical trials, addressing remote health challenges during COVID-19, and how to engage in the IC program.
Related Resources:
The newly released IEEE 2791-2020 Standard for Bioinformatics Analyses Generated by High-Throughput Sequencing (HTS) facilitates an expedited bioinformatics communications exchange protocol amongst critical stakeholders in the clinical research phase.
Maria Palombini, Director of Emerging Communities & Opportunities Development and Healthcare and Life Sciences (HLS) Practice Lead at IEEE Standards Association (IEEE SA), interviews Raja Mazumder and Jonathon Keeney to shine a spotlight on the many different use cases from submissions for FDA regulatory review, to potential COVID-19 antibody research and other vaccine and infectious disease development applications.
Related Resources:
In the inaugural edition of the “IEEE Blockchain Podcast Series,” Alpesh Shah, Sr. Director, Global Business Strategy and Intelligence for IEEE, sits down with Dr. Bryant Gilot, MD, CMO of Blockchain Health Co., to discuss on what blockchain is, the practical applications on how it can be used, and what is needed to get us there.
Alpesh and Bryant will discuss the impact blockchain technologies will have on 21st century problems such as healthcare management, how the new General Data Protection Regulation (GDPR) may impact blockchain, and the ethical concerns of implementing blockchain.
Part 1 (10:34)
Groundbreaking Technology Key for Improving Clinical Studies, Unlocking and Securing Data and Enhancing Patient Safety and Engagement. Learn more about the Blockchain for Clinical Trials Forum.
Counterfeit medicine is a rapidly rising global epidemic. The size and scope of the issue are reaching a point where the World Health Organization can only roughly estimate that the number of counterfeit meds in the market range from 10-30%. In this latest Blockchain Podcast Series episode, you’ll hear from Carlos Sanchez and Robert Panetta from BlockRx on how the BlockRx Pharma ecosystem is addressing this issue.
In August 2017, IEEE Standards Association (IEEE-SA) sponsored a groundbreaking, independent research study focused on the State of Blockchain Adoption on the Pharmaceutical Supply Chain. This study will offer detailed insights on unresolved issues, expectations and commitment towards adoption of blockchain for the pharmaceutical supply chain. The research is being conducted by an independent, industry-recognized, third-party research firm which will survey an adequate sample of key partners on the chain including pharma manufacturers, wholesalers, pharmacy benefit managers, and dispensaries.
From the publisher's feed